• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

Recent Advances in the Study of 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine (CAS: 1289079-12-4)

4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine (CAS: 1289079-12-4) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, biological activity, and potential therapeutic uses, particularly in the context of kinase inhibition and anticancer therapies. This research brief aims to summarize the latest findings related to this compound, providing a comprehensive overview of its current status in the scientific community.

The compound's structural features, including the azetidine and pyrimidine moieties, make it a promising scaffold for the development of novel kinase inhibitors. Kinases play a critical role in cell signaling pathways, and their dysregulation is often associated with various diseases, including cancer. Recent research has demonstrated that 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine exhibits potent inhibitory activity against specific kinases, such as EGFR (Epidermal Growth Factor Receptor) and VEGFR (Vascular Endothelial Growth Factor Receptor), which are key targets in oncology.

In a recent study published in the Journal of Medicinal Chemistry, researchers explored the synthetic pathways for 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine and its derivatives. The study highlighted the compound's versatility as a building block for further chemical modifications, enabling the development of more selective and potent kinase inhibitors. The researchers also reported on the compound's pharmacokinetic properties, including its stability and bioavailability, which are critical factors for its potential use in clinical settings.

Another significant development involves the application of 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine in combination therapies. Preclinical studies have shown that when used in conjunction with other anticancer agents, the compound enhances therapeutic efficacy and reduces drug resistance. This synergistic effect is particularly promising for the treatment of aggressive cancers, such as glioblastoma and non-small cell lung cancer (NSCLC).

Despite these advancements, challenges remain in the development of 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine as a therapeutic agent. Issues such as off-target effects and toxicity profiles need to be addressed through further research and optimization. Ongoing studies are focusing on structure-activity relationship (SAR) analyses to refine the compound's properties and improve its selectivity for target kinases.

In conclusion, 4-(Azetidin-1-yl)-6-chloro-2-methylpyrimidine (CAS: 1289079-12-4) represents a promising candidate for the development of next-generation kinase inhibitors. Its unique structural features and biological activity make it a valuable tool in the fight against cancer and other kinase-related diseases. Future research will likely focus on optimizing its pharmacological properties and exploring its potential in clinical trials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)